Please ensure Javascript is enabled for purposes of website accessibility Jacqueline Wen Dai | Huatai Securities (USA)
Home > Research > Our Analysts > Health Care > Jacqueline Wen Dai

Health Care

Jacqueline Wen Dai
Jacqueline Wen Dai
Jacqueline Wen Dai
Lead Analyst, China Healthcare

Jacqueline serves as the Lead Analyst of the China Healthcare team, covering pharma, biotech, devices, Traditional Chinese Medicine (TCM), and health care services, across both H & A shares. Prior to joining Huatai Securities, she worked in the Global Research Department of HSBC and CICC (Shanghai).

Jacqueline has a Bachelor of Science in Biological Sciences, and a Ph.D. in Nanoscience Technology from Hong Kong University of Science and Technology.

In the 2020 poll, her team was ranked #2 Best Analyst Team under Healthcare category (mainland). In 2019, Jacqueline placed second in the Institutional Investor All-China poll in her sector (mainland) and runner-up (international). She placed 1st and 2nd in 2017 and 2018, for the institutional investors “All China” category.